We are experiencing some temporary issues. The market data on this page is currently delayed. Please bear with us as we address this and restore your personalized lists.
S&P Futures
5,178.50 +11.00 (+0.21%) Dow Futures
38,307.00 +69.00 (+0.18%) Nasdaq Futures
18,224.00 +44.75 (+0.25%) Russell 2000 Futures
2,029.70 +9.90 (+0.49%) Crude Oil
85.43 -0.23 (-0.27%) Gold
2,371.00 -3.10 (-0.13%)
After hours:
Chart Events
Performance Outlook
| Previous Close | 125.40 |
| Open | 126.74 |
| Bid | 124.10 x 1300 |
| Ask | 124.51 x 900 |
| Day's Range | 124.35 - 127.06 |
| 52 Week Range | 75.56 - 138.28 |
| Volume | |
| Avg. Volume | 5,073,711 |
| Market Cap | 564.564B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | 46.46 |
| EPS (TTM) | 2.68 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.37 (1.10%) |
| Ex-Dividend Date | Mar 22, 2024 |
| 1y Target Est | 141.32 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for NVO
Related Research
- Novo Nordisk A/SAnalyst Report: Novo Nordisk A/SWith roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.RatingFair ValueEconomic Moat13 days agoMorningstar
Investor's Business DailyNvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level
Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.
BloombergEli Lilly, Novo Euphoria Risks Disappointing Investors, Goldman Says
(Bloomberg) -- The weight loss drug frenzy that’s driven Eli Lilly & Co. and Novo Nordisk A/S to record peaks is raising the stakes for investors, according to Goldman Sachs Group Inc. analysts.Most Read from BloombergIsrael Versus Iran — What an Open War Between Them Could Look LikeTexas Warns of Possible Power Emergency Next WeekBiden Returns to White House as Israel Braces for Iran ResponseIsrael, Allies Mostly Block Unprecedented Attack From IranA $150 Billion Fortune Bolsters Qatari Royals
BioPharma DiveEuropean regulator concludes no suicide link to obesity drugs
The decision clears a concern hanging over GLP-1 medicines like Ozempic since reports of suicidal ideation and self-harm among people taking the drugs surfaced in July.
Investor's Business DailyIs Eli Lilly Stock A Buy Or A Sell After FDA Delays Its Alzheimer's Drug Decision?
The FDA will now hold an advisory committee meeting to discuss Eli Lilly's Alzheimer's drug, donanemab. Is Eli Lilly stock a buy or a sell?
ZacksNovo Nordisk (NVO) Gains As Market Dips: What You Should Know
In the closing of the recent trading day, Novo Nordisk (NVO) stood at $124.93, denoting a +0.06% change from the preceding trading day.
Insider MonkeyInsiders are Piling into These 10 Healthcare Stocks in 2024
In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 Healthcare Stocks in 2024. Healthcare investors were nervous when 2024 started, since election years usually don’t bode well for healthcare stocks. But […]
MarketWatchThis weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?
GLP-1 medications will likely expand beyond their current uses for diabetes or weight loss, according to money managers at Tema
Motley Fool2 Healthcare Stocks to Buy Hand Over Fist in April
Don't wait too long to invest in these exciting stocks.
Motley FoolNovo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development
It may not be too late to invest in this promising healthcare stock, even though it may look expensive.
FortuneMajor investors say AstraZeneca boss is ‘massively underpaid’ on $21.5 million salary, despite earning more than double Novo Nordisk’s CEO
Shareholder advisors are urging investors to vote against Pascal Soriot's proposed $2.3 million raise, arguing it is excessive.
Morningstar Rating
Rating
Fair Value
Economic Moat
People Also Watch
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| LLY Eli Lilly and Company | |||
| NVS Novartis AG | |||
| SMCI Super Micro Computer, Inc. | |||
| SNY Sanofi | |||
| AZN AstraZeneca PLC |
Similar to NVO
| Symbol | Last Price | Change | % Change |
|---|---|---|---|
| VKTX Viking Therapeutics, Inc. | |||
| VRTX Vertex Pharmaceuticals Incorporated | |||
| MRNA Moderna, Inc. | |||
| CRSP CRISPR Therapeutics AG | |||
| ALPN Alpine Immune Sciences, Inc. |
Analyst Price Targets (7)
Upgrades & Downgrades
| Initiated | BMO Capital: to Outperform | 4/12/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/20/2024 | |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 3/8/2024 | |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 2/20/2024 |
Company Profile
Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 63,370
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
